KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) Enterprise Value (2018 - 2026)

Bionano Genomics (BNGO) has disclosed Enterprise Value for 9 consecutive years, with -$13.3 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value fell 39.91% to -$13.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$13.3 million through Dec 2025, down 39.91% year-over-year, with the annual reading at -$13.3 million for FY2025, 39.91% down from the prior year.
  • Enterprise Value hit -$13.3 million in Q4 2025 for Bionano Genomics, up from -$21.6 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$5.1 million in Q4 2022 to a low of -$362.1 million in Q1 2021.
  • Historically, Enterprise Value has averaged -$115.7 million across 5 years, with a median of -$65.2 million in 2023.
  • Biggest five-year swings in Enterprise Value: plummeted 4369.84% in 2021 and later skyrocketed 97.97% in 2022.
  • Year by year, Enterprise Value stood at -$250.6 million in 2021, then soared by 97.97% to -$5.1 million in 2022, then plummeted by 1211.55% to -$66.8 million in 2023, then skyrocketed by 85.81% to -$9.5 million in 2024, then plummeted by 39.91% to -$13.3 million in 2025.
  • Business Quant data shows Enterprise Value for BNGO at -$13.3 million in Q4 2025, -$21.6 million in Q3 2025, and -$16.5 million in Q2 2025.